December 1, 2021
Werewolf Therapeutics to Present Preclinical Data on INDUKINE™ Molecules at the 63rd American Society of Hematology (ASH) Annual Meeting
Data demonstrates the strength of Werewolf’s innovative therapeutic approach across multiple conditionally activated pipeline programs CAMBRIDGE, Mass., Dec. 01, 2021